Cochrane
Library

Cochrane Database of Systematic Reviews

Early versus deferred treatment for early stage multiple myeloma (Review)

He Y, Wheatley K, Glasmacher A, Ross H, Djulbegovic B

He Y, Wheatley K, Glasmacher A, Ross H, Djulbegovic B.
Early versus deferred treatment for early stage multiple myeloma.
Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD004023.
DOI: [10.1002/14651858.CD004023](https://doi.org/10.1002/14651858.CD004023).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	3
OBJECTIVES	3
METHODS	3
RESULTS	4
Figure 1.	5
Figure 2.	5
Figure 3.	5
Figure 4.	6
Figure 5.	6
DISCUSSION	6
AUTHORS' CONCLUSIONS	7
ACKNOWLEDGEMENTS	7
REFERENCES	8
CHARACTERISTICS OF STUDIES	9
DATA AND ANALYSES	11
Analysis 1.1. Comparison 1 Outcome, Outcome 1 Mortality.	12
Analysis 1.2. Comparison 1 Outcome, Outcome 2 Progression.	12
Analysis 1.3. Comparison 1 Outcome, Outcome 3 Response.	12
Analysis 1.4. Comparison 1 Outcome, Outcome 4 Vertebral compression.	13
Analysis 1.5. Comparison 1 Outcome, Outcome 5 Acute leukemia.	13
ADDITIONAL TABLES	13
APPENDICES	15
WHAT'S NEW	16
HISTORY	16
CONTRIBUTIONS OF AUTHORS	16
DECLARATIONS OF INTEREST	16
SOURCES OF SUPPORT	16
INDEX TERMS	16

[Intervention Review]

Early versus deferred treatment for early stage multiple myeloma

Yulong He¹, Keith Wheatley², Axel Glasmacher³, Hamish Ross⁴, Benjamin Djulbegovic⁵

¹Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland. ²Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK. ³University of Bonn, Bonn, Germany. ⁴Northampton General Hospital NHS Trust, Northampton, UK. ⁵Professor of Medicine and Oncology, H. Lee Moffitt Cancer Center, Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA

Contact address: Benjamin Djulbegovic, Professor of Medicine and Oncology, H. Lee Moffitt Cancer Center, Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida, USF Health Clinical Research,, 12901 Bruce B. Downs Boulevard, MDC02, Tampa, Florida, 33612, USA. bdjulbeg@health.usf.edu, benjamin.djulbegovic@moffitt.org.

Editorial group: Cochrane Haematological Malignancies Group.

Publication status and date: Edited (no change to conclusions), published in Issue 4, 2012.

Citation: He Y, Wheatley K, Glasmacher A, Ross H, Djulbegovic B. Early versus deferred treatment for early stage multiple myeloma. *Cochrane Database of Systematic Reviews* 2012, Issue 4. Art. No.: CD004023. DOI: [10.1002/14651858.CD004023](https://doi.org/10.1002/14651858.CD004023).

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Early stage multiple myeloma (MM) represents about 20% of MM. Most of the patients are asymptomatic. Thus, it is far less dramatic than advanced disease and may require different treatment strategies. For these patients, it is not clear whether it is better to start chemotherapy right after the diagnosis or to delay the treatment until symptoms become obvious as the disease progresses.

Objectives

To identify and synthesize all available research evidence on whether early treatment intervention results in improved clinical outcomes when compared with observation alone. The main outcomes of interest that were examined included mortality, disease progression, response rate, and toxicity of early treatment.

Search methods

Searches of the following electronic databases were undertaken: MEDLINE, EMBASE, CANCELIT, LILLIACS and Cochrane Database of RCTs. We have recently compiled a comprehensive database of RCTs in myeloma. This search was updated and supplemented by hand-search of abstracts from main society meetings such as the ASH (American Society of Hematology), ASCO (American Society of Clinical Oncology), and EHA (European Haematology Association). In addition, we compared our list with a list of RCTs maintained by the Oxford Clinical Trial Service Unit.

Selection criteria

Randomized controlled trials (RCT) with a parallel design that compared early versus deferred treatment of patients with early stage multiple myeloma based on Durie-Salmon (D-S) staging system. We also considered those trials that did not define early stage myeloma according to D-S staging system, but enrolled patients according to clinical uncertainty about the benefits of immediate intervention.

Data collection and analysis

Data synthesis was performed for all studies and according to the defined quality criteria. The first reviewer and the contact reviewer of this proposal independently extracted data. Disagreement was resolved by consensus. Revman software (4.1) was used to combine results from all studies and expressed as an overall odds ratio or Peto's Odds Ratio, with 95% confidence interval.

Main results

Three trials were included with a total of 131 patients in each of the early treatment and deferred treatment groups. Early MM is asymptomatic stage I in these trials. All trials used standard Melphalan treatment but not stem cell transplantation. No statistically significant heterogeneity among the studies was detected. Beneficial effects of early treatment were seen in delay of myeloma progression (Peto's OR = 0.16, 95% CI: 0.09 to 0.29), and reduced vertebral compression (OR = 0.18, 95% CI: 0.02 to 1.59, NNT = 23, 95% CI: an NNT of 11, via infinity, to an NNH of 50). No significant effects on mortality and response rate were seen (Peto's OR = 1.11, 95% CI: 0.67 to 1.84, and OR = 0.63, 95% CI: 0.33 to 1.23, respectively). Early treatment may increase the risk of acute leukemia (Peto's OR = 3.20, 95% CI: 0.55 to 18.73, NNH = 44, 95% CI: an NNT of 63, via infinity, to an NNH of 15).

Authors' conclusions

Early treatment of early stage multiple myeloma inhibits disease progression, and may reduce vertebral compression. However, early treatment may increase the risk of acute leukemia. However, the data on vertebral compression and leukemic transformation may not be interpretable due to very small numbers. Based on the current evidence, mortality and response rate are not significantly affected by introducing early treatment in the progression of myeloma. However, it is quite possible that the lack of beneficial effects of early intervention in myeloma is a false negative result due to the paucity of the existing evidence. In addition, data on quality of life and toxicity were sparsely reported adding to additional difficulties about management decisions in early stage myeloma.

PLAIN LANGUAGE SUMMARY

Early treatment for early stage multiple myeloma may slow the disease progression but does not appear to improve survival

Multiple myeloma (MM) is cancer of the bone marrow. It causes bone destruction that leads to pain, spinal cord compression and fractures. In early stages, most people do not show any symptoms of MM. It is not clear whether it is better to start treatment with cancer drugs straight after diagnosis, or to wait until symptoms of the disease appear. The review of trials found that early treatment slows the progression of the disease. However, there is not enough evidence, due to too few studies conducted in patients with early stage myeloma to show that early treatment improves the survival of people with MM.

BACKGROUND

Multiple myeloma (MM) is a disease characterized by the neoplastic proliferation of a clone of plasma cells secreting immunoglobulins (Alexanian 1994; Hussein 1994). It represents about 10% of hematological malignancies and is the ninth leading cause of cancer deaths in African Americans (Landis 1998). Currently, myeloma is considered an incurable disease. The goal of treatment and prognosis in myeloma depends, to the large extent, on the stage of the disease at presentation (Alexanian 1994; Anderson 1998). In patients who are symptomatic and present in advanced stages, such as a stage IIA to IIIB according to Durie-Salmon (D-S) staging system (Durie 1975), the goal of treatment is effective palliation and prolongation of survival. In these patients, a treatment with combined chemotherapy was found not to be superior to conventional chemotherapy of melphalan-prednisone (MPH-P) (Myeloma 1998). In recent years, aggressive high-dose chemotherapy with stem-cell transplant has emerged as the treatment of choice for advanced, symptomatic myeloma (Attal 1996).

Early stage multiple myeloma, i.e. stage I according to D-S staging system, represents about 20% of MM (Riccardi 2000). Most of the patients with stage I MM are asymptomatic. Thus, it is far less dramatic than advanced disease and may require different treatment strategies. For patients with stage I MM, it is not clear whether it is better to start chemotherapy right after the diagnosis or to delay the treatment until symptoms become obvious as disease progresses.

Several retrospective studies have suggested that early MM patients do not benefit from aggressive chemotherapies, while more advanced patients do (Harley 1979; Salmon 1983; Cooper 1986). Currently, treatment is not recommended for asymptomatic patients in early stage disease according to D-S staging system. This recommendation is based on data derived from several small randomized controlled trials. Two randomized studies (Hjorth 1993; Riccardi 1994) have suggested that delayed treatment had no influence on survival as compared with early treatment. Another study has demonstrated that deferring treatment may be a reasonable alternative to immediate chemotherapy, and immediate treatment does not prolong long-term survival compared with treatment at the disease progression (Riccardi 2000).

To provide the most reliable assessment of existing evidence to guide practitioners regarding optimal therapeutic approach, a research synthesis of the total available evidence on the management of early stage myeloma is needed but has never been performed.

It is necessary to perform a systematic review of the available randomized controlled trials to obtain conclusive evidence as to whether early treatment intervention results in improved clinical outcomes for early stage MM patients, when compared with deferred treatment. Based on the totality of the available evidence, better recommendations for practice can be made.

OBJECTIVES

To identify and synthesize all available research evidence which attempts to answer the question whether early treatment intervention results in improved clinical outcomes when compared

with observation alone. The main outcomes of interest to be examined in this project include mortality, progression, response rate, and toxicity of early treatment.

METHODS

Criteria for considering studies for this review

Types of studies

Included: randomized controlled trials (RCT) with a parallel design that compared early versus deferred treatment of patients with early stage multiple myeloma based on Salmon-Durie (D-S) staging system. We also considered those trials that did not define early stage myeloma according to D-S staging system, but enrolled the patients according to clinical uncertainty about the benefits of immediate intervention. No such studies were identified. Patients had to be initially randomized either to observation or to up-front treatment with chemotherapy. Only studies that included clinical outcomes, such as overall survival, progression-free survival and/or toxicity of treatment were eligible for our meta-analysis.

Types of participants

Patients with early stage myeloma according to Salmon-Durie (D-S) staging system (stage I), or where there is uncertainty about the benefit of immediate treatment.

Types of interventions

Experimental group: Treatment intervention at early stage of myeloma.

Control group: observation (deferred treatment until progression of the disease).

Types of outcome measures

Primary outcomes

- Overall mortality
- Progression
- Response rate

Secondary outcomes

- Toxicity of early treatment
- Effects of alkylator therapy (e.g. MDS, and acute leukemia)
- Quality of life (pain, fatigue, anxiety)

Search methods for identification of studies

Electronic searches

To identify RCTs of interest, searches of the following electronic databases were undertaken:

- MEDLINE,
- EMBASE,
- CANCERLIT,
- LILLIACS and
- Cochrane Database of RCTs.

In MEDLINE published studies were identified using comprehensive search strategies for identification of randomized controlled trials (RCTs) described by Dickersin, et al (Dickersin 1994) (1966-2001)

and (Robinson 2002) for year 2002. This methodologic search strategy was combined with added terms (see Appendix 1).

Cochrane Controlled Trials Register was searched (all years, latest issue 02/2002) using key words (see Appendix 2).

LILACS (1982 June 2002) according to the optimal search strategy described by Castro et al (Castro 1997), with the added terms ((MYELOMA OR MIELOMA) AND (MULTIPLO OR MULTIPLE)).

EMBASE (1974 - December 2000) using the search strategy kindly provided by Julie Glanville of the NHS Centre for Reviews and Dissemination, University of York, UK (combined with added terms related to multiple myeloma, see):

Searching other resources

All relevant references in each article were also scanned.

Additional strategies used were to contact researchers in the field and handsearched abstracts from the meetings of

- ASH (American Society of Hematology),
- ASCO (American Society for Clinical Oncology) from 1993 to 2001 and
- EHA (European Haematology Association) from 1993 to 2001.

The authors of each selected paper were also contacted. In addition, we compared our list with a list of RCTs maintained by the Oxford Clinical Trial Service Unit.

This search formed a basis for creation of a comprehensive database of RCTs in myeloma (Djulgovic 2002). This database currently contains information on 165 RCTs in myeloma and 3 meta-analysis. From this database, 3 trials met our eligibility criteria and were included in our analysis (see below).

We believe that our search has been most comprehensive attempt to date to identify all RCTs in myeloma (Djulgovic 2001). A comprehensive search is very important because failure to include all studies - published or unpublished - may result in biased results (Clarke 1999).

Data collection and analysis

Quality assessment of the trials and data extraction:

To reliably and accurately evaluate any health care intervention, studies have to be of the highest quality. A number of the quality dimensions in the design and conduct of a trial have been described which, if violated, may lead to biased assessment. In general, assessment of the quality revolves about evaluation for possible effect of bias and random error in the design of trials, which will affect the internal and external validity of the trials (Juni 2001; Egger 2001). The most important quality criteria are the appropriateness of randomization, allocation concealment, blinding of assessment of outcomes of interest, intention to treat analysis, pre-specified b-error (power analysis), and pre-specified a-error (Altman 2001; Verhagen 1998). The effect of random errors is minimized by pooling data in meta-analysis. A method of Jadad, which combines some of these quality dimensions in a reproducible quality score was also used to complement a component-based approach in the quality assessment (Jadad 1996; Jadad 1998). We should note that Jadad's scale pays particular attention to the effect of blinding,

which in our systematic review is unimportant since the main outcome of interest is death.

Each selected study was assessed according to these quality criteria. Data synthesis was performed for all studies and according to each quality criterion. This allows detection of any bias in the analysis. The first reviewer and the contact reviewer of this proposal independently extracted data. Disagreement was resolved by consensus.

Statistical methods:

Since main outcomes of interest are overall mortality and progression, the hazard ratio was extracted for each study using methods described by Parmar et al (Parmar 1998). Revman software (4.1) was used to combine results from all studies and express as an overall odds ratio or Peto's Odds Ratio (Clarke 1999), with 95% confidence interval, where OR = 1.0 indicates no difference between observation and early treatment. Peto's method was used to test for heterogeneity between studies combined in the final analysis, following the RevMan handbook (Clarke 1999). Toxicity was extracted and calculated as the number of patients experiencing a given event using the standard odds ratio (Clarke 1999). After data were extracted, they were then sent to the authors of each identified study for verification and/or update. However, we did not hear back from these authors and thus the data remained the same as were initially extracted.

RESULTS

Description of studies

In our list of 156 RCTs on multiple myeloma, we identified three studies on early versus deferred treatment for early stage disease. 6 additional RCTs were identified in Oxford's database that were not in our list, but none were eligible for our meta-analysis (Those six RCTs will be supplemented to our RCT list). New updated search of MEDLINE and Cochrane Database of RCTs from 2000 to present identified 5 additional RCTs on multiple myeloma, but none of them were eligible for our analysis either.

Characteristics of included studies shows the characteristics of included studies, and their quality assessment.

Risk of bias in included studies

Two studies got a Jadad score of 3 out of 5 (Riccardi 1994; Riccardi 2000), and the other got a score of 2 (Hjorth 1993). Randomization seems to be adequate in all three studies, while allocation concealment is not well described in one study (Hjorth 1993). Withdrawals and dropouts were described in all three studies. None of the studies described power analysis. The most recent study (Riccardi 2000) had a sample size larger than the others, but overall, sample sizes were very small in those trials.

Effects of interventions

In the three trials eligible for meta-analysis, a total of 131 patients with early stage multiple myeloma were treated at the diagnosis, compared with 131 patients with same disease treated at the disease progression. Mortality was extractable from all three studies. Progression and response data were incomplete (only available for one group, either the early treatment group or the deferred treatment group) for Hjorth 1993 and Riccardi 1994, respectively, and thus only two studies were combined for

those outcomes. There were no extractable data on hematological, gastrointestinal, or renal toxicity (reported by fewer than 2 trials); two trials reported vertebral compression (Hjorth 1993; Riccardi 2000). All three trials reported acute leukemia development.

Mortality

There were 64 deaths among 131 patients with early treatment, and 59 deaths among 131 patients with deferred treatment. The

Peto's OR is 1.11 (95% CI: 0.67 to 1.84, Figure 1). No heterogeneity was detected by the Chi-square test (Chi-square = 3.56, df = 2, P = 0.17). Results indicate that there is no evidence of a beneficial effect of early treatment on mortality in patients with early stage multiple myeloma. However, it is possible that this is a false-negative result (see discussion).

Figure 1. Forest plot of comparison: 1 Outcome, outcome: 1.1 Mortality.

Progression

Two studies were included (Riccardi 1994; Riccardi 2000), with a total of 106 patients in the early treatment group and 106 patients in the deferred treatment group. 9 patients progressed after treatment at diagnosis while 46 did when treatment was

deferred, resulting in a Peto's OR of 0.16 (95% CI: 0.09 to 0.29, Figure 2), indicating a statistically significant improvement (P < 0.00001) associated with early treatment. No significant heterogeneity between the two studies was detected (Chi-square = 2.75, df = 1, P = 0.097).

Figure 2. Forest plot of comparison: 1 Outcome, outcome: 1.2 Progression.

Response Rate

Two studies were included (Hjorth 1993; Riccardi 2000), with 100 patients treated at the disease diagnosis and 56 patients treated because of the disease progression. 43 among the 100 and 31

among the 56 responded to treatment, corresponding to an OR of 0.63 (95% CI: 0.33 to 1.23, Figure 3). The difference is not significant, neither is the heterogeneity between the two studies (Chi-square = 0.56, df = 1, P = 0.45).

Figure 3. Forest plot of comparison: 1 Outcome, outcome: 1.3 Response.

Vertebral compression

Two studies reported vertebral compression in the deferred treatment group (Hjorth 1993; Riccardi 2000). None of the 97 patients with early treatment developed a vertebral compression, while 4 out of 91 patients in the deferred treatment group suffered from the disease. OR takes a value of 0.18 (95%CI: 0.02 to 1.59,

Figure 4), favoring the early treatment, but without significant difference at conventional statistical level (P = 0.12). The NNT for vertebral compression is 23, with 95% CI from an NNT of 11, via infinity, to an NNH of 50. No heterogeneity was detected (Chi-square = 1.54, df = 1, P = 0.99).

Figure 4. Forest plot of comparison: 1 Outcome, outcome: 1.4 Vertebral compression.

Acute leukemia

All three studies provided data on acute leukemia. 4 out of 131 patients in the early treatment group and 1 out of 131 in the deferred treatment group developed acute leukemia, with a Peto's OR of 3.20 (95% CI: 0.55 to 18.73, [Figure 5](#)). Results suggest that

early treatment may cause more risk for acute leukemia, although the difference does not have enough statistical significance. The NNH for acute leukemia is 44, with 95% CI from an NNT of 63, via infinity, to an NNH of 15. No heterogeneity was found between the two included studies (Chi-square = 0.63, df = 1, P = 0.43).

Figure 5. Forest plot of comparison: 1 Outcome, outcome: 1.5 Acute leukemia.

Additional information is shown in [Table 1](#), [Table 2](#), [Table 3](#).

DISCUSSION

The goal of this systematic review and meta-analysis is to synthesize all available data on the effect of early treatment for early stage multiple myeloma. There are several interesting findings in our meta-analysis.

First of all, the mortality is not significantly affected with early treatment or with deferred treatment. However, when we compared the progression rate, we see a considerable benefit of early treatment, indicating that early treatment inhibits the disease progression. Similarly, more patients experienced a vertebral compression in the deferred treatment group than those in the early treatment group did (4 out of 91 versus 0 out of 97). The difference is not statistically significant, either because there actually is no difference or due to small sample sizes. Our analysis showed that whether the treatment is administered right after the diagnosis or at the disease progression did not affect the response rate. However, interpretation needs to be made carefully due to the wide range of the confidence interval. We should also keep in mind that only patients who got the treatment in the deferred group (i.e. those with disease progression) contributed to the analysis. Since they are a selected group out of the whole deferred arm, comparison with the whole early treatment arm may not be informative. Based on these results, early treatment seems to have the beneficial effect in terms of inhibiting disease progression, but other beneficial effects remain to be further analyzed.

We had planned to extract data on toxicity to determine the adverse effect of early treatment. However, due to the lack of

adequate information provided by the three papers, only leukemia development data could be extracted. In terms of leukemia development, we see that early treatment may increase the risk of developing acute leukemia, a potential harm associated with early treatment, which is the only adverse effect that we see in our meta-analysis. We should note here that the number of events is small and the results still can be explained by chance. This is one of the reasons that we requested long-term follow-up data from the investigators to examine if the results presented here would still hold. Unfortunately, to date we have not received a response from them.

Other toxicity data were not extractable and we were not sure whether or not it was because no toxicity was seen in the trials, or the investigators did not report treatment related hazards. In terms of other patient-oriented outcomes, we were not able to extract any quality of life data, and no conclusion can be made in this respect.

While assessing the quality of the studies, we noticed that all three papers, especially the early two, had small sample sizes, and were seriously under-powered. No power analysis was predetermined in any of these trials. The meta-analysis based on the three studies may also have low power to detect treatment effects, and may explain why we see no significant difference between the two groups in most of the outcomes that we examined. Given the fact that highly significant early treatment effect was detected in delaying progression of the disease, one has to wonder if the negative results in the mortality reduction are true-negative or false-negative results.

For example, we calculated sample size based on the formula provided by Pogue and Yusuf ([Pogue 1997](#)). To reliably detect

15% mortality difference between two treatment groups (with significance level $\alpha = 0.05$), the meta-analysis should at least include 350 patients (as opposed to 262 patients in the current analysis). Our meta-analysis had power of 70% to detect this difference. This means that there is 30% of chance that the conclusion that the early intervention does not change mortality in multiple myeloma could be a false-negative result. If we assume more realistic treatment difference of about 10% reduction between the two therapeutic arms, then we would have to enroll 800 patients in the study. To detect such a difference, our meta-analysis with 262 patients will only have a power of 51%, which means that the chance to get a false-negative result is 49%. Despite the fact that we believe that we identified all trials that have ever investigated the issue of early intervention in myeloma, it appears that the totality of available evidence is simply inadequate to help us draw reliable conclusions about the role of chemotherapy in early stage myeloma.

In short, there is clear evidence that early therapy delays progression but no evidence that this leads to better survival. Data on vertebral compression and leukemia development are not interpretable because of the very small numbers of events. Future trials need to be performed about other aspects of the treatment such as cost and patient preferences, supplemented by more complete information about toxicity and quality of life, to help make decision on whether to treat early stage multiple myeloma at the disease diagnosis or wait until the disease progression. Much more important though is the need for further much larger trials to address this question reliably.

AUTHORS' CONCLUSIONS

Implications for practice

Early treatment of early stage multiple myeloma clearly inhibits disease progression, but does not improve survival. Results on vertebral compression and acute leukemia need to be verified by additional trials with larger sample size.

Implications for research

It is possible that the results in terms of the effect of early intervention on mortality of myeloma are false-negative. Further analysis of the effect of early treatment of early stage multiple myeloma should be conducted, based on a larger sample size, and more complete outcome data, including toxicity and quality of life. Such an analysis should help demonstrate the cost-effectiveness of early treatment, and provide recommendations for treatment of early stage multiple myeloma.

ACKNOWLEDGEMENTS

We would like to acknowledge the help of Ambuj Kumar, M.D., with the initial RCT identification process. Thilo Kober (Cochrane Hematological Malignancies Group, Cologne, Germany) provided important support in all phases of the registration, preparation and submission of title, protocol and review.

The editorial base of the Cochrane Haematological Malignancies Group is funded, as part of the Competence Network Malignant Lymphomas, by the German Ministry of Education and Research (BMBF).

REFERENCES

References to studies included in this review

Hjorth 1993 {published data only}

Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. *European Journal of Haematology* 1993;**50**(2):95-102..

Riccardi 1994 {published data only}

Riccardi A, Ucci G, Luoni R, Brugnatelli S, Mora O, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Alberio F, et al. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma. *British Journal of Cancer* 1994;**70**(6):1203-10..

Riccardi 2000 {published data only}

Riccardi A, Mora O, Tinelli C, Valentini D, Brugnatelli S, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Giordano M, Delfini C, Nicoletti G, Bergonzi C, Rinaldi E, Piccinini L, Ascarì E. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. *British Journal of Cancer* 2000;**82**(7):1254-60..

Additional references

Alexanian 1994

Alexanian R, Dimopoulos M. The treatment of multiple myeloma. *The New England Journal of Medicine* 1994;**330**(7):484-9..

Altman 2001

Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. *Annals of Internal Medicine* 2001;**134**(8):663-94..

Anderson 1998

Anderson KC, Noga SJ, Bensinger Wea. NCCN practice guidelines for multiple myeloma.. *Oncology* 1998;**12**:317-51.

Attal 1996

Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. *The New England Journal of Medicine* 1996;**335**(2):91-7..

Castro 1997

Castro AA, Clark AO, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS).. *Revista paulista de medicina* 1997;**115**:1423-1426.

Clarke 1999

Clarke M, Oxman AD. Cochrane Reviewer's Handbook 4.1 [update July 2000]. Oxford: The Cochrane Collaboration; Review Manager (Revman) 4.1. 1999.

Cooper 1986

Cooper MR, McIntyre OR, Propert KJ, Kochwa S, Anderson K, Coleman M, Kyle RA, Prager D, Rafla S, Zimmer B. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. *Journal of Clinical Oncology* 1986;**4**(9):1331-9..

Dickersin 1994

Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. *Bmj* 1994;**309**(6964):1286-91..

Djulgovic 2001

Djulgovic B, Adams JR, Lyman GH, 23.Djulgovic B, Adams JR, Lyman GH, et al. Evaluation and appraisal of randomized controlled trials in myeloma.. *Ann Oncology* 2001;**12**:1611-1617.

Djulgovic 2002

Djulgovic B, Clark O, Hozo I. Database for health outcomes and quality of randomized trials in multiple myeloma. *Proceeding of American Society of Clinical Oncology* 2002;**21**:251a.

Durie 1975

Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer* 1975;**36**(3):842-54..

Egger 2001

Egger M, Smith DS, Altman D. Systematic reviews in health care.. London: *BMJ Books* 2001;**2nd ed.**:87-108.

Harley 1979

Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. *Blood* 1979;**54**(1):13-22..

Hussein 1994

Hussein M. Multiple myeloma: an overview of diagnosis and management. *Cleveland Clinic Journal of Medicine* 1994;**61**(4):285-98..

Jadad 1996

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. *Controlled Clinical Trials* 1996;**17**(1):1-12..

Jadad 1998

Jadad A. Randomized Controlled Trials.. London: *BMJ Books*. 1998.

Juni 2001

Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *Bmj* 2001;**323**(7303):42-6..

Landis 1998

Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. *CA: a Cancer Journal for Clinicians* 1998;**48**(1):6-29..

Myeloma 1998

Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. *Journal of Clinical Oncology* 1998;**16**(12):3832-42..

Parmar 1998

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;**17**(24):2815-34..

Pogue 1997

Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. *Controlled Clinical Trials* 1997;**18**(6):580-93; discussion 661-6..

Robinson 2002

Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. *International Journal of Epidemiology* 2002;**31**(1):150-3..

Salmon 1983

Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BG, Dixon DO. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. *Journal of Clinical Oncology* 1983;**1**(8):453-61..

Shakespeare 2001

Shakespeare TP, Gebiski VJ, Veness MJ, Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. *Lancet* 2001;**357**(9265):1349-53..

Verhagen 1998

Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. *Journal of Clinical Epidemiology* 1998;**51**(12):1235-41..

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Hjorth 1993

Methods	RCT ITT-Yes Jadad=2 Power analysis not described Duration of follow-up: 5 yr
Participants	Stage I MM (Asymptomatic) Durie and Salmon Early treatment: Enrolled 25, analyzed 25; Deferred treatment: Enrolled 25, analyzed 25
Interventions	Melphalan (MPH): 0.25mg/kg prednisone (P): 2 mg/kg 4 days, 6 week intervals
Outcomes	Mortality Progression Response Vertebral compression Renal insufficiency Leukemia
Notes	Not double-blind

Early versus deferred treatment for early stage multiple myeloma (Review)

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Hjorth 1993 (Continued)

Withdrawals and dropouts described

Risk of bias

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B - Unclear

Riccardi 1994

Methods	RCT ITT-No Jadad=3 Power analysis not described Duration of follow-up: 3 yr
Participants	Stage I MM Durie and Salmon Early treatment: Enrolled 38, analyzed 34; Deferred treatment: Enrolled 40, analyzed 40
Interventions	MPH: 0.21mg/kg 4 days, P: 0.5 mg/kg 10 days, 6 week intervals
Outcomes	Mortality Progression Response Leukemia
Notes	Not double-blind Withdrawals and dropouts described

Risk of bias

Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	A - Adequate

Riccardi 2000

Methods	RCT ITT-No Jadad=3 Power analysis not described Duration of follow-up: 6 yr
---------	---

Riccardi 2000 (Continued)

Participants	Stage I MM Durie and Salmon Early treatment: Enrolled 75, analyzed 72; Deferred treatment: Enrolled 70, analyzed 66 (all patients evaluable for response)
Interventions	MPH: 0.21mg/kg 4 days, P: 0.5 mg/kg 10 days, 6 week intervals
Outcomes	Mortality Progression Response Osteolysis Hypercalcemia Vertebral compression Renal insufficiency Leukemia
Notes	Not double-blind Withdrawals and dropouts described
Risk of bias	
Bias	Authors' judgement Support for judgement
Allocation concealment (selection bias)	Low risk A - Adequate

DATA AND ANALYSES

Comparison 1. Outcome

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality	3	262	Peto Odds Ratio (95% CI)	1.11 [0.67, 1.84]
2 Progression	2	212	Peto Odds Ratio (95% CI)	0.16 [0.09, 0.29]
3 Response	2	156	Odds Ratio (M-H, Fixed, 95% CI)	0.63 [0.33, 1.23]
4 Vertebral compression	2	188	Odds Ratio (M-H, Fixed, 95% CI)	0.18 [0.02, 1.59]
5 Acute leukemia	3	262	Peto Odds Ratio (95% CI)	3.20 [0.55, 18.72]

Analysis 1.1. Comparison 1 Outcome, Outcome 1 Mortality.

Analysis 1.2. Comparison 1 Outcome, Outcome 2 Progression.

Analysis 1.3. Comparison 1 Outcome, Outcome 3 Response.

Analysis 1.4. Comparison 1 Outcome, Outcome 4 Vertebral compression.

Analysis 1.5. Comparison 1 Outcome, Outcome 5 Acute leukemia.

ADDITIONAL TABLES

Table 1. Type and content of reporting in RCTs on early stage multiple myeloma (A)

Study ID	Mortality	Progression	Response	Relapse	Quality of life	Pain
Hjorth 1993	Yes	Incomplete	Yes	No	No	Incomplete
Riccardi 1994	Yes	Yes	Yes	No	No	No
Riccardi 2000	Yes	Yes	Yes	No	No	No
Extractable	3	2	3	0	0	0

Table 2. Type and content of reporting in RCTs on early stage multiple myeloma (B)

Study ID	Bone disease	Hypercalcemia	Vertebral compress	Hematological	Gastrointestinal	Renal	Leukemia
Hjorth 1993	Incomplete	Incomplete	Yes	No	No	Incomplete	Yes
Riccardi 1994	No	No	No	No	No	No	Yes
Riccardi 2000	Yes	Yes	Yes	No	No	Yes	Yes
Extractable	1	1	2	0	0	1	3

Table 3. Outcome criteria

Study ID	Progression	Response
Hjorth 1993	Increasing serum M protein IgG>50g/l, IgA>30g/l, or Bence Jones proteinuria >4g/l, bone pains and osteolytic bone lesions or hypercalcemia, anemia or rising serum creatinine	Reduction in M protein of >50%
Riccardi 1994	>25% increase in MC (mono-clonal component) and/or an increase in BMPC (bone marrow plasma cell) of at least 20% and/or worsening of laboratory parameters (hemoglobin, serum calcium, and blood urea nitrogen) and/or of skeletal lytic lesions	Reduction in MC, drop in BMPC of <20%, 2g/dl rise in Hb, normal serum calcium, serum albumin >3g/dl
Riccardi 2000	Increase in MC, appearance/enlargement of bone lesions, anemia (Hb<10g/dl), hypercalcemia, renal failure	Reduction in MC, drop in BMPC of <20%, 2g/dl rise in Hb, normal serum calcium, serum albumin >3g/dl

APPENDICES

Appendix 1. MEDLINE search strategy

MYELOMA ,
 MYELOM* ,
 MULTIPLE MYELOMA ,
 PLASMACYTOMA ,
 PLASMOCYTOM* and PLASM?CYTOM* (free text and MESH)

Appendix 2. CENTRAL search strategy

MYELOMA ,
 MYELOM* ;
 MULTIPLE MYELOMA ,
 PLASMACYTOM* ;
 PLASMOCYTOM* .

Appendix 3. EMBASE search strategy

1 explode "clinical-trial"/ all subheadings
 2 "double-blind-procedure"/ all subheadings
 3 "single-blind-procedure"/ all subheadings
 4 "crossover-procedure"/ all subheadings
 5 "evaluation"/ all subheadings
 6 "follow-up"/ all subheadings
 7 "prospective-study"/ all subheadings
 8 "clinical-article"/ all subheadings
 9 "major-clinical-study"/ all subheadings
 10 "prospective-study"/ all subheadings
 11 "placebo"/ all subheadings
 12 "randomization"/ all subheadings
 13 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
 14 explode "comparative-study"/ all subheadings

15 "meta-analysis"/ all subheadings
16 #14 or #15
17 ((intervention or clinical*) near (trial* or study or studies)) in ti,ab
18 (random* or placebo* or rct*) in ti,ab
19 ((singl* or doubl* or trebl* or tripl*) with (blind* or mask*)) in ti,ab
20 explode "controlled-study"/ all subheadings
21 ((control or controls or controlled) with (trial* or study or studies)) in ti,ab
22 ((multi or multic*) with (trial* or study or studies)) in ti,ab
23 ((cross over or crossover or evaluation or prospectiv*) with (trial* or study or studies)) in ti,ab
24 ((follow or follow-up or followup) with (studies or study or trial*)) in ti,ab
25 #13 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24

WHAT'S NEW

Date	Event	Description
13 March 2012	Amended	Additional tables linked to text.

HISTORY

Protocol first published: Issue 4, 2002
Review first published: Issue 4, 2002

Date	Event	Description
15 August 2008	Amended	Converted to new review format.

CONTRIBUTIONS OF AUTHORS

BD oversaw and participated in all phases of the project, coordinated the group activity, and maintained contact with the Cochrane Collaboration. YH wrote the draft of the review and edited it. YH searched and extracted data. KW provided statistical expertise. AG hand-searched and extracted data. KW and AG helped with drafting and provided assistance with statistics, data analysis and data presentation. OC and JR helped with drafting.

DECLARATIONS OF INTEREST

Ben Djulbegovic is serves on the editorial board of the Cochrane Haematology Malignancy Group.

SOURCES OF SUPPORT

Internal sources

- H Lee Moffitt Cancer Center and Research Institute (This work was performed as part of the fulfilment for MPH degree for YH), USA.

External sources

- No sources of support supplied

INDEX TERMS

Medical Subject Headings (MeSH)

Disease Progression; Multiple Myeloma [pathology] [*therapy]; Randomized Controlled Trials as Topic; Time Factors

MeSH check words

Humans